Abstract
Glioblastoma multiforme (GBM) is one of the most aggressive and treatment-resistant brain tumors, with a median survival of only 15 months after diagnosis. This project aims to investigate the potential of DNA aptamers, in combination with standard chemotherapy (temozolomide - TMZ) to modulate epigenetic pathways in GBM. The aptamer Apt9, previously characterized as having high affinity f…